|
AU2015261559A1
|
|
Treatment of cognitive disorders with (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
|
|
AU2014201637A1
|
|
Tetrasubstituted benzenes
|
|
WO2013142269A1
|
|
Imidazotriazinone compounds
|
|
WO2013106678A1
|
|
Tetrasubstituted benzenes
|
|
WO2013106328A1
|
|
Tetrasubstituted benzenes for treatment of early onset alzheimer's disease
|
|
CN103747681A
|
|
Methods of treatment of limited cognitive impairment
|
|
WO2012154710A1
|
|
Treatment of cognitive disorders with certain alpha-7 nicotinic acid receptor agonists in combination with nicotine
|
|
EP2640378A1
|
|
Treatment of inflammation with certain alpha-7 nicotinic acid receptor agonists in combination with acetylcholinesterase inhibitors
|
|
BR112013001939A2
|
|
treatment of cognitive disorders with certain alpha-7-nicotinic acid receptor agonists in combination with acetylcholinesterase inhibitors
|
|
AU2011256287A1
|
|
A crystalline form of (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate
|
|
CN102802620A
|
|
Treatment of cognitive disorders with certain alpha-7 nicotinic acid receptors in combination with acetylcholinesterase inhibitors
|
|
TW201016211A
|
|
Tetrasubstituted benzenes
|
|
WO2010006130A2
|
|
Pde-10 inhibitors
|
|
AU2009262150A1
|
|
Di-substituted phenyl compounds as phosphodiesterase 10 inhibitors
|
|
WO2009137503A1
|
|
Hdac inhibitors and uses thereof
|
|
WO2009137462A2
|
|
Methods for treating cognitive disorders using inhibitors of histone deacetylase
|
|
WO2009137499A1
|
|
Inhibitors of histone deacetylase
|
|
CN101945848A
|
|
Tetrasubstituted benzenes
|
|
US2011040094A1
|
|
1,3,4-trisubstituted benzenes
|
|
WO2008064296A1
|
|
Method of treating neurological disorders with carbonic anhydrase inhibitors
|
